Premium
Eltrombopag, low‐dose rituximab, and dexamethasone combination as frontline treatment of newly diagnosed immune thrombocytopaenia
Author(s) -
GómezAlmaguer David,
ColungaPedraza Perla R.,
GómezDe León Andrés,
GutiérrezAguirre César H.,
CantúRodríguez Olga G.,
JaimePérez José C.
Publication year - 2019
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.15070
Subject(s) - eltrombopag , medicine , rituximab , prednisone , romiplostim , thrombopoiesis , dexamethasone , gastroenterology , immune thrombocytopenia , antibody , platelet , immunology , thrombopoietin , haematopoiesis , megakaryocyte , genetics , stem cell , biology
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom